Literature DB >> 18359403

CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Adam T Whaley-Connell1, James R Sowers, Lesley A Stevens, Samy I McFarlane, Michael G Shlipak, Keith C Norris, Shu-Cheng Chen, Yang Qiu, Changchun Wang, Suying Li, Joseph A Vassalotti, Allan J Collins.   

Abstract

BACKGROUND: The prevalence of chronic kidney disease (CKD) is increasing in the United States, caused in part by older age and increasing prevalences of hypertension and type 2 diabetes. CKD is silent and undetected until advanced stages. The study of populations with earlier stages of kidney disease may improve outcomes of CKD.
METHODS: The Kidney Early Evaluation Program (KEEP), a National Kidney Foundation program, is a targeted community-based health-screening program enrolling individuals 18 years and older with diabetes, hypertension, or family history of kidney disease, diabetes, or hypertension. Participants who had received transplants or were on regular dialysis treatment were excluded from this analysis. The National Health and Nutrition Examination Survey (NHANES) 1999-2004 was a nationally representative cross-sectional survey; participants were interviewed in their homes and/or received standardized medical examinations in mobile examination centers.
RESULTS: Of the 61,675 KEEP participants, 16,689 (27.1%) were found to have CKD. In the NHANES sample of 14,632 participants, 2,734 (15.3%) had CKD. Older age, smoking, obesity, diabetes, hypertension, and cardiovascular disease were associated significantly with CKD in both KEEP and NHANES (P < 0.05 for all). Of note, the likelihood for CKD in African Americans differed between KEEP (odds ratio, 0.81; P < 0.001) and NHANES (odds ratio, 1.10; P = 0.2).
CONCLUSION: A greater prevalence of CKD was detected in the KEEP screening than in the NHANES data. KEEP has the limitations common to population-screening studies and conclusions for population-attributable risk may be limited. The targeted nature of the KEEP screening program and the large sample size with clinical characteristics comparable to NHANES validates KEEP as a valuable cohort to explore health associations for the CKD and at-risk-for-CKD populations in the United States.

Entities:  

Mesh:

Year:  2008        PMID: 18359403     DOI: 10.1053/j.ajkd.2007.12.016

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  72 in total

1.  Environmental tobacco smoke furthers progression of diabetic nephropathy.

Authors:  David M Obert; Ping Hua; Meagan E Pilkerton; Wenguang Feng; Edgar A Jaimes
Journal:  Am J Med Sci       Date:  2011-02       Impact factor: 2.378

2.  Multidisciplinary team care may slow the rate of decline in renal function.

Authors:  Elizabeth A Bayliss; Bharati Bhardwaja; Colleen Ross; Arne Beck; Diane M Lanese
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 8.237

3.  A Case for Early Screening for Diabetic Kidney Disease.

Authors:  Adam Whaley-Connell; Kunal Chaudhary; Madhukar Misra; Ramesh Khanna
Journal:  Cardiorenal Med       Date:  2011-10-05       Impact factor: 2.041

Review 4.  Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP).

Authors:  Peter A McCullough; Susan Steigerwalt; Kirit Tolia; Shu-Cheng Chen; Suying Li; Keith C Norris; Adam Whaley-Connell
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

Review 5.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

6.  Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.

Authors:  N Naganathar; W -P Yau; Z H Mok; Z Y F Tan; S T H Chew
Journal:  Osteoporos Int       Date:  2021-03-15       Impact factor: 4.507

Review 7.  Uric acid as a mediator of diabetic nephropathy.

Authors:  Diana I Jalal; David M Maahs; Peter Hovind; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

8.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

9.  The See Kidney Disease Targeted Screening Program for CKD.

Authors:  Lauren E Galbraith; Paul E Ronksley; Lianne J Barnieh; Joanne Kappel; Braden J Manns; Susan M Samuel; Min Jun; Rob Weaver; Nadine Valk; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

Review 10.  Chronic kidney disease following acute kidney injury-risk and outcomes.

Authors:  Kelvin C W Leung; Marcello Tonelli; Matthew T James
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.